We seek to support providers in expediting diagnosis and access to care.
Cognoa is developing digital products intended to support healthcare providers in expediting diagnosis with the goal of improving access to timely intervention for children and families, starting with autism spectrum disorder (ASD).
Because most ASD-specific interventions require an ASD diagnosis, delays in diagnosis can result in missed opportunities during a critical window in the child’s neurodevelopment.
Gordon-Lipkin E, et al. Pediatr Clin North Am. 2016;63(5):851-859.
Oswald DP, et al. Focus Autism Dev Disabil. 2017;32(2):152-160.
Taylor LJ, et al. BMJ Open. 2016;6(9):e012517.
Zuckerman KE, et al. J Pediatr. 2015;166(6):1431–1439.
While a child as young as 18 months can be reliably diagnosed with ASD, multiple factors have driven the average age of diagnosis to 4 years and 3 months, an average delay of 3 years between parental concern and a formal ASD diagnosis.
Estes A, et al. J Am Acad Child Adolesc Psychiatry. 2015;54(7):580-587.
Hyman SL, et al. Pediatrics. 2020;145(1):e20193447.
MacDonald R, et al. Res Dev Disabil. 2014;35(12):3632-3644.
Mandell DS, et al. Am J Public Health. 2009;99(3):493-498.
Oswald DP, et al. Focus Autism Dev Disabil. 2017;32(2):152-160.Peters-Sheffer N, et al. Res Autism Spectr Disord. 2011;5(1):60-69.
Strain PS, Bovey EH. Topics in Early Childhood Special Education. 2011;31(3):133-154.
Zwaigenbaum L, et al. Autism Res. 2016 Jul;9(7):790-800.
Cognoa is developing products to help providers address gaps in care.
We strive to serve the healthcare community with products that:
Demonstrate efficacy through clinical studies
Integrate into existing provider workflows
Help facilitate more equitable access to diagnosis and care
Demonstrate Efficacy Through Clinical Studies
Integrate Into Existing Provider Workflows
Help Facilitate More Equitable Access to Diagnosis and Care
Our Lead Products
FDA MARKETING AUTHORIZATION
The First Digital
Diagnosis Aid for Autism
Canvas Dx™ harnesses clinically validated artificial intelligence (AI) technology to aid physicians in diagnosing ASD in children between the ages of 18 and 72 months who are at risk of developmental delay. The Software as a Medical Device (SaMD) is the first FDA-authorized diagnosis aid designed to help physicians diagnose autism in the primary care setting.
IN DEVELOPMENT
Digital Therapeutic
Cognoa’s digital therapeutic for children living with autism received FDA Breakthrough Device Designation and is currently in design and development.
Connect with Cognoa
If you are a healthcare provider in the U.S. and are interested in learning more about Cognoa and/or our diagnosis aid, Canvas Dx™, visit CognoaConnect.com
If you have questions regarding Cognoa’s clinical data, please contact our Medical Affairs team: medaffairs@cognoa.com